Alignment Healthcare: Conservative Guidance, Solid EBITDA Trajectory, and Limited Regulatory Risk Support Buy Rating and $25 Target

Analyst Ryan Langston of TD Cowen reiterated a Buy rating on Alignment Healthcare, retaining the price target of $25.00.

Ryan Langston has given his Buy rating due to a combination of factors, including stronger-than-expected recent EBITDA performance and management’s history of issuing cautious guidance that often proves conservative. He notes that the company’s 2026 EBITDA outlook aligns with prior commentary, and his modest upward revision to future EBITDA reinforces confidence in the earnings trajectory and supports maintaining a $25 price target based on 2027 enterprise value to revenue.

Langston also highlights that Alignment Healthcare appears well positioned against regulatory changes, with minimal risk exposure to chart-review coding and a view that proposed Stars and measure adjustments should be largely neutral over time. He further underscores that expected medical loss ratio seasonality is already reflected in guidance, suggesting that near-term volatility is manageable and that the long-term growth and profitability profile justifies a Buy recommendation.

In another report released today, TipRanks – Google also reiterated a Buy rating on the stock with a $23.50 price target.